selective EP300 degrader

Foghorn Therapeutics is developing a selective EP300 protein degrader, a small molecule therapeutic designed to induce the targeted degradation of the EP300 (p300) protein. EP300 is a histone acetyltransferase and transcriptional co-activator that plays a critical role in chromatin remodeling. The program focuses on treating cancers with a synthetic lethal dependency on EP300, particularly those harboring mutations in the paralogous gene CBP (CREBBP), as well as other EP300-dependent malignancies. Preclinical data indicates efficacy in androgen receptor-positive (AR+) prostate cancer, diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. Notably, the selective degradation of EP300 avoids the platelet-related toxicities often associated with dual EP300/CBP inhibition. The program is currently in preclinical development, with IND-enabling studies projected for 2026.

Other names

EP300 protein degraderEP-300 protein degraderEP 300 protein degraderselective p300 degrader